Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
RSP vs VHT: how they differ
RSP and VHT hold 11% of their weight in the same names, and VHT returned more over the year.
Invesco S&P 500 Equal Weight ETF and Vanguard Health Care Index Fund.
What they hold in common
By the books each fund has filed, RSP and VHT hold 11% of their money in the same securities at the same weight.
| Holding | RSP | VHT |
|---|---|---|
| Centene Corp. | 0.29% | 0.46% |
| Humana Inc. | 0.27% | 0.58% |
| Elevance Health, Inc. | 0.25% | 1.35% |
| UnitedHealth Group Inc. | 0.25% | 5.46% |
| West Pharmaceutical Services, Inc. | 0.24% | 0.37% |
| Cigna Group (The) | 0.21% | 1.17% |
| CVS Health Corp. | 0.21% | 1.83% |
| Viatris Inc. | 0.21% | 0.30% |
| Mettler-Toledo International Inc. | 0.20% | 0.38% |
| Waters Corp. | 0.20% | 0.60% |
| Bristol-Myers Squibb Co. | 0.20% | 1.84% |
| Incyte Corp. | 0.19% | 0.26% |
| Only in RSP | Only in VHT |
|---|---|
| Intel Corp. 0.38% | Alnylam Pharmaceuticals Inc 0.63% |
| Seagate Technology Holdings PLC 0.34% | Natera Inc 0.47% |
| Advanced Micro Devices, Inc. 0.33% | Veeva Systems Inc 0.43% |
| ON Semiconductor Corp. 0.33% | REVOLUTION Medicines Inc 0.40% |
| Sandisk Corp. 0.32% | Illumina Inc 0.39% |
| Western Digital Corp. 0.31% | Insmed Inc 0.36% |
| Ciena Corp. 0.30% | United Therapeutics Corp 0.36% |
| Monolithic Power Systems, Inc. 0.29% | Neurocrine Biosciences Inc 0.25% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and May 31, 2026.
| RSP Invesco S&P 500 Equal Weight ETF | VHT Vanguard Health Care Index Fund | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Invesco | Vanguard |
| What it is | S&P 500 equal weight | Health Care |
| Total return, 1 year | +14.8% | +21.6% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −2.7 pts | +4.1 pts |
| Expense ratio | 0.20% | 0.09% |
| Already in the S&P 500 | 99.1% | 85.6% |
| Holdings | 503 | 401 |
RSP in plain words
RSP is an index equity fund tracking the S&P 500 equal weight. Over the year to Sep 11, 2026 it returned +14.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.20% a year. By its holdings filed for Apr 30, 2026, 99% of the fund by weight is stocks the S&P 500 also holds, across 503 positions, with the top ten at 3.2%. It sat 3.5% below its high of Aug 14, 2026 on Sep 11, 2026.
VHT in plain words
VHT is an index equity fund tracking the Health Care. Over the year to Sep 11, 2026 it returned +21.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.09% a year. By its holdings filed for May 31, 2026, 86% of the fund by weight is stocks the S&P 500 also holds, across 401 positions, with the top ten at 52.0%. It sat 5.7% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, RSP or VHT?
- In the year to Sep 12, 2026, with distributions reinvested, RSP returned +14.8% and VHT returned +21.6%, so VHT returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, RSP or VHT?
- RSP charges 0.20% a year and VHT charges 0.09%, so VHT is cheaper. Fees come from each fund's prospectus.
- How much do RSP and VHT overlap with the S&P 500?
- By their latest filed holdings, 99% of RSP and 86% of VHT by weight is stocks the S&P 500 already holds. Between the two funds, 11% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, RSP against VHT, data as of Sep 12, 2026. https://etfiq.com/compare/any/RSP-VHT Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources